EXACT Sciences Corporation (EXAS) Shares are Up 10.76%

EXACT Sciences Corporation (EXAS) : Traders are bullish on EXACT Sciences Corporation (EXAS) as it has outperformed the S&P 500 by a wide margin of 51.11% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.29%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.76% in the last 1 week, and is up 54.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

EXACT Sciences Corporation (NASDAQ:EXAS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $19.21 and $19.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.25, notching a gain of 1.32% for the day. The total traded volume was 4,589,999 . The stock had closed at $19.00 on the previous day.

The stock has recorded a 20-day Moving Average of 31.17% and the 50-Day Moving Average is 68.46%. Exact Sciences Corporation is up 225.17% in the last 3-month period. Year-to-Date the stock performance stands at 108.56%.

EXACT Sciences Corporation (EXAS) : Average target price received by EXACT Sciences Corporation (EXAS) is $15.33 with an expected standard deviation of $5.52. The most aggressive target on the stock is $26, whereas the most downbeat target is $8. 9 financial analysts are currently covering the stock.


Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.